Tesamorelin

Also known as: Egrifta, TH9507

**Mechanism of Action** Tesamorelin is a synthetic stabilized analog of growth hormone-releasing hormone (GHRH), designed to restore endogenous growth hormone (GH) secretion. By binding to GHRH receptors on pituitary somatotrophs, it stimulates pulsatile GH release, subsequently elevating insulin-like growth factor 1 (IGF-1) levels. This activation of the GH/IGF-1 axis promotes lipolysis and reduces visceral adipose tissue (VAT) accumulation, particularly in patients with HIV-associated lipodystrophy, where GH deficiency is common. Unlike recombinant GH, tesamorelin preserves the physiological pulsatility of GH secretion, potentially reducing adverse metabolic effects. **Key Research Findings** Clinical trials (e.g., Phase III studies) demonstrate that tesamorelin (2 mg/day subcutaneous) significantly reduces VAT by 15–20% over 26 weeks in HIV patients with lipodystrophy, with sustained effects during long-term use. Improvements in triglyceride levels and body composition are observed, though no significant changes in subcutaneous fat or glycemic control are noted. Adverse effects include arthralgias, injection-site reactions, and transient increases in IGF-1 levels. Long-term safety data (up to 2 years) show no increased risk of neoplasia or glucose intolerance, though monitoring of IGF-1 and HbA1c is recommended. **Clinical Relevance** Tesamorelin is FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is the only GHRH analog specifically indicated for this condition, offering a targeted approach to VAT reduction without the systemic risks of exogenous GH. Its use is contraindicated in patients with active malignancies, pituitary disorders, or hypersensitivity. Ongoing research explores its potential in non-HIV metabolic disorders, including obesity and nonalcoholic fatty liver disease (NAFLD), though these remain investigational. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides